---
title: "What's Going On With Esperion Therapeutics Stock On Monday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285093535.md"
description: "Esperion Therapeutics shares rose on Monday following a $1.1 billion buyout deal with Archimed, offering shareholders $3.16 per share in cash and contingent value rights (CVR) linked to future U.S. sales. The acquisition represents a 58% premium over the stock's closing price on April 30. The CVR includes potential milestone payments based on sales of specific products through 2030. Esperion also recently agreed to acquire Corstasis Therapeutics for $75 million upfront, with additional potential payments totaling up to $180 million."
datetime: "2026-05-04T15:25:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285093535.md)
  - [en](https://longbridge.com/en/news/285093535.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285093535.md)
---

# What's Going On With Esperion Therapeutics Stock On Monday?

**Esperion Therapeutics** (NASDAQ:ESPR) shares are up on Monday as the company is set to go private via a $1.1 billion deal with **Archimed**.

The acquisition will provide Esperion shareholders with $3.16 per share in cash at closing. Potential milestone payments are tied to future sales performance.

Esperion shareholders will receive $3.16 per share in cash plus one non-tradeable contingent value right (CVR), representing a premium of 58% to the stock’s closing price on April 30.

The transaction is expected to close soon, according to the May 1 announcement.

**Read Also: BrightSpring Extends Rally With Solid Q1, Upgraded Fiscal 2026 Forecast**

The CVR will entitle the shareholder to participate in two contingent milestone payments of up to $100 million in the aggregate as follows: 

-   A contingent milestone payment based on annual U.S. net sales of certain products containing bempedoic acid in calendar year 2027.
-   A contingent milestone payment based on annual U.S. net sales of certain products containing bumetanide equal to $60 million in the aggregate if such annual net sales equal or exceed $160 million in any single calendar year through December 31, 2030.

In March, Esperion Therapeutics agreed to acquire **Corstasis Therapeutics**, which developed Enbumyst, the first FDA-approved nasal spray diuretic for treating edema associated with congestive heart failure.

The deal includes an upfront cash payment of $75 million, along with potential royalties and milestone payments that could total up to $180 million.

**ESPR Stock Price Activity:** Esperion Therapeutics shares were trading at $3.10 at the time of publication on Monday, according to Benzinga Pro data.

**Read Also: Michael Saylor Pauses Bitcoin Buys, But A $3B Acquisition Frenzy Could Start This Week, Analyst Says**

_Image: Shutterstock_

### Related Stocks

- [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md)
- [BTSG.US](https://longbridge.com/en/quote/BTSG.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)
- [BTSGU.US](https://longbridge.com/en/quote/BTSGU.US.md)

## Related News & Research

- [Esperion cleared for merger by German antitrust authority; stockholder vote set for July 8](https://longbridge.com/en/news/289231651.md)
- [Key facts: Esperion Expands 2024–25 Programs; Estimates Fall 781.6%](https://longbridge.com/en/news/285820903.md)
- [Esperion Therapeutics to Be Acquired by Essence Parent for $3.16 Per Share Plus CVR Up to $100M](https://longbridge.com/en/news/284917768.md)
- [Esperion (ESPR) was downgraded to a Hold Rating at Needham](https://longbridge.com/en/news/285108916.md)
- [Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary](https://longbridge.com/en/news/289047115.md)